Eligo Bioscience formed based on research from the Lu Lab at MIT and the Marraffini Lab at Rockefeller University. From 2014-2017 Eligo was incubated at the Institut Pasteur in Paris and now resides at the Paris Biotech Santé at Cochin Hospital.
Eligo Bioscience develops Eligobiotics, which are nano-delivery vehicles that are based on non-replicative phage particles that are engineered and programmed to package synthetic genetic circuits.
In 2014 two Nature Biotechnology papers by group members describe programmable, sequence-specific antimicrobials that use CRISPR-Cas9 system with the potential to manipulate complex bacterial populations. Eligo describes these types of targeted antimicrobials as “Editing the microbiome”.
Their antimicrobials do not edit bacterial DNA, rather the delivered CRIPSR-Cas system cuts up and destroys the DNA of the target bacteria.The group has used their system to selectively remove a specific strain of bacteria from the gut of mice while keeping the other microflora intact.
On July 9, 2015 Eligo Bioscience completed their seed funding round with €2.6M from Seventure Partners (lead investor) and Worldwide Innovation Challenge.
Eligo Bioscience raises a $20,000,000 series A round from Seventure Partners and Khosla Ventures.
Eligo Bioscience was founded.
Dr. David Bikard
Dr. Xavier Duportet
Prof. Luciano Marraffini
Prof. Timothy Lu, MD-PhD
Documentaries, videos and podcasts
- Cluster: Microbiome and gut healthA cluster of topics related to microbiome and gut health.
- CRISPR/Cas ToolsClustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR associated (Cas) proteins perform adaptive immune functions in prokaryotic organisms defending against foreign nucleic acids such as viruses. CRISPR/Cas tools have been adapted for use in genome editing and other DNA and RNA targeting applications.
- Cluster: Synthetic biologyA cluster of topics related to synthetic biology.